Etophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) side effects
sponsored
Vomiting, Nausea, Restlessness, Nervousness, Frequent urge to urinate, Allergic reaction, Flushing, Diarrhoea, Abdominal pain, Headache, Insomnia, Irritation, Loss of appetite, Tremor
What is Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION)?
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) injection is used together with other medicines to treat the acute symptoms of asthma, bronchitis, emphysema, and other lung diseases in a hospital setting.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) belongs to a group of medicines known as bronchodilators. Bronchodilators are medicines that relax the muscles in the bronchial tubes (air passages) of the lungs. They relieve cough, wheezing, shortness of breath, and troubled breathing by increasing the flow of air through the bronchial tubes.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is available only with your doctor's prescription.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Oral
Acute bronchospasm
Adult: Patients not taking Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) or other xanthine medication: Loading dose: 5 mg/kg.
Child: ≥1 yr Same as adult dose.
Elderly: Lower doses should be used.
Hepatic impairment: Reduce dose.
Oral
Chronic bronchospasm
Adult: 300-1,000 mg in divided doses 6-8 hrly. As modified-release preparation: 175-500 mg 12 hrly.
Child: <6 yr Not recommended; 6-12 yr 20-35 kg: 120-250 mg bid; >12 yr 250-500 mg bid.
Elderly: Lower doses should be used.
Hepatic impairment: Reduce dose.
Intravenous
Acute severe bronchospasm
Adult: Patients not taking Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) or other xanthine medication: Loading dose: 4-5 mg/kg by infusion over 20-30 min. Maintenance dose: 0.4-0.6 mg/kg/hr.
Child: Patients not taking Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) or other xanthine medication: Loading dose: 4-5 mg/kg by infusion over 20-30 min. Maintenance dose: 1-9 yr Initially, 0.8-1 mg/kg/hr; >9-12 yr Initially, 0.7-0.77 mg/kg/hr.
Elderly: Lower doses should be used.
Hepatic impairment: Reduce dose.
Incompatibility: Y-site: Cefepime, hetastarch in normal saline, phenytoin, ceftazidime. Syringe: Ceftriaxone.
Special Populations: Reduce dose in patients w/ cor pulmonale, heart failure, liver disease and fever. Smokers and those who consume alcohol may require higher maintenance dose.
How should I use Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION)?
Use Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Some foods may change the effectiveness or increase the side effects of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION). Talk to your doctor about how you should take Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) with regard to food. Do not suddenly change your diet or eating habits without first checking with your doctor.
Swallow Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) whole. Do not break, crush, or chew before swallowing.
Take Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) at about the same time(s) each day. If you are using more than 1 dose per day, try to take the second dose 10 to 12 hours after your first dose and before the evening meal. Check with your doctor or pharmacist if you have questions about how to take Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION).
If you are using 1 dose per day, take Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) in the morning unless your doctor tells you otherwise.
Continue to take Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) even if you feel well. Do not miss any doses.
If you miss a dose of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION), skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION).
Uses of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Use: Labeled Indications
Reversible airflow obstruction:
Oral: Treatment of symptoms and reversible airflow obstruction associated with chronic asthma, or other chronic lung diseases (eg, emphysema, chronic bronchitis).
Injection: Treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases (eg, chronic bronchitis, emphysema) as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids. Guideline recommendations:
Guideline recommendations:
Asthma: The 2019 Global Initiative for Asthma Guidelines (GINA) and the 2007 National Heart, Lung and Blood Institute Asthma Guidelines recommends against Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) as a long-term control medication for asthma in children ≤5 years of age. Additionally, GINA guidelines do not recommend Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) for asthma in children 6 to 11 years of age.
Oral Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is a potential alternative option (not preferred) in adolescents and adults as a long-term control medication in mild asthma or as an add-on long-term control medication in moderate to severe asthma; however, a stepwise approach using inhaled corticosteroids (+/- inhaled long-acting beta agonists depending on asthma severity) is preferred to Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) due to efficacy concerns and potential for adverse events (GINA 2019). Both guidelines recommend against Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) for the treatment of asthma exacerbations due to poor efficacy and safety concerns (GINA 2019; NAEPP 2007).
COPD: Based on the Global Initiative for Chronic Obstructive Lung Disease Guidelines (2019), use of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) in patients with COPD is controversial and lacks data. Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) may favorably impact functional impairment in COPD patients, but exact effects are unclear. Studies that demonstrated improvement were done with slow-release preparations. Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is not a preferred agent for COPD exacerbations due to its potential for toxicity.
Off Label Uses
Bradycardia, heart transplantation
Data from small observational studies suggest that Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) may be beneficial for the treatment of bradycardia following heart transplantation.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is a chiral compound. The racemic mixture can be divided into its optical antipodes: levo- and dextro-amphetamine. Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, e.g., MDMA (Ecstasy) and the N-methylated form, methamphetamine. Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is a homologue of phenethylamine.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) (Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) anhydrous capsule) ®, like other extended-release Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) products, is intended for patients with relatively continuous or recurring symptoms who have a need to maintain therapeutic serum levels of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION). It is not intended for patients experiencing an acute episode of bronchospasm (associated with asthma, chronic bronchitis, or emphysema). Such patients require rapid relief of symptoms and should be treated with an immediate-release or intravenous Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) preparation (or other bronchodilators) and not with extended-release products.
Patients who metabolize Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) at a normal or slow rate are reasonable candidates for once-daily dosing with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) (Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) anhydrous capsule) ®. Patients who metabolize Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) rapidly (e.g., the young, smokers, and some nonsmoking adults) and who have symptoms repeatedly at the end of a dosing interval, will require either increased doses given once a day or preferably, are likely to be better controlled by a schedule of twice-daily dosing. Those patients who require increased daily doses are more likely to experience relatively wide peak-trough differences and may be candidates for twice-a-day dosing with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) (Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) anhydrous capsule) ®.
Patients should be instructed to take this medication each morning at approximately the same time and not to exceed the prescribed dose.
Recent studies suggest that dosing of extended-release Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) products at night (after the evening meal) results in serum concentrations of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) which are not identical to those recorded during waking hours and may be characterized by early trough and delayed peak levels. This appears to occur whether the drug is given as an immediate-release, extended-release, or intravenous product. To avoid this phenomenon when two doses per day are prescribed, it is recommended that the second dose be given 10 to 12 hours after the morning dose and before the evening meal.
Food and posture, along with changes associated with circadian rhythm, may influence the rate of absorption and/or clearance rates of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) from extended-release dosage forms administered at night. The exact relationship of these and other factors to nighttime serum concentrations and the clinical significance of such findings require additional study. Therefore, it is not recommended that
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) (Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) anhydrous capsule) ® (when used as a once-a-day product) be administered at night.
Patients who require a relatively high dose of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) (i.e., a dose equal to or greater than 900 mg or 13 mg/kg, whichever is less) should not take Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) (Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) anhydrous capsule) ® less than 1 hour before a high-fat-content meal since this may result in a significant increase in peak serum level and in the extent of absorption of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) as compared to administration in the fasted state.
The steady-state peak serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration is a function of the dose, the dosing interval, and the rate of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) absorption and clearance in the individual patient. Because of marked individual differences in the rate of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance, the dose required to achieve a peak serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance (e.g., 400-1600 mg/day in adults < 60 years old and 10-36 mg/kg/day in children 1-9 years old). For a given population there is no single Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) dose that will provide both safe and effective serum concentrations for all patients. Administration of the median Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) dose required to achieve a therapeutic serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration in a given population may result in either sub-therapeutic or potentially toxic serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations in individual patients. For example, at a dose of 900 mg/day in adults < 60 years or 22 mg/kg/day in children 1-9 years, the steady-state peak serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration will be < 10 mcg/mL in about 30% of patients, 10-20 mcg/mL in about 50% and 20-30 mcg/mL in about 20% of patients. The dose of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) must be individualized on the basis of peak serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.
Transient caffeine-like adverse effects and excessive serum concentrations in slow metabolizers can be avoided in most patients by starting with a sufficiently low dose and slowly increasing the dose, if judged to be clinically indicated, in small increments. Dose increases should only be made if the previous dosage is well tolerated and at intervals of no less than 3 days to allow serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations to reach the new steady state. Dosage adjustment should be guided by serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration measurement. Health care providers should instruct patients and care givers to discontinue any dosage that causes adverse effects, to withhold the medication until these symptoms are gone and to then resume therapy at a lower, previously tolerated dosage.
If the patient's symptoms are well controlled, there are no apparent adverse effects, and no intervening factors that might alter dosage requirements, serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations should be monitored at 6 month intervals for rapidly growing children and at yearly intervals for all others. In acutely ill patients, serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations should be monitored at frequent intervals, e.g., every 24 hours.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight. Table V contains Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) dosing titration schema recommended for patients in various age groups and clinical circumstances. Table VI contains recommendations for Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) dosage adjustment based upon serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations. Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration.
Table V. Dosing initiation and titration (as anhydrous Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION)).*
A. Children (12-15 years) and adults (16-60 years) without risk factors for impaired clearance.
Titration Step
Children < 45 kg
Children > 45 kg and adults
1. Starting Dosage
12-14 mg/kg/day up to a maximum of 300 mg/day divided Q 24 hrs*
300-400 mg/day Dose reduction and/or serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance occur (e.g., sustained fever), or a drug that interacts with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is added or discontinued.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION)® 200 mg capsules are red-orange and clear, with markings Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION), 200 mg, ucb, and 2842, supplied as:
NDC Number
Size
50474-200-01
bottle of 100
50474-200-50
bottle of 500
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION)® 300 mg capsules are red and clear, with markings Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION), 300 mg, ucb, and 2852, supplied as:
NDC Number
Size
50474-300-01 50474-300-50
bottle of 100 bottle of 500
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION)® 400 mg capsules are pink and clear, with markings Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION), 400 mg, ucb, and 2902, supplied as:
NDC Number
Size
50474-400-01
bottle of 100
Storage
Store below 77 °F (25 °C).
FOR MEDICAL INFORMATION Contact: Medical Affairs Department Phone: (800) 477-7877, Fax: (770) 970-8859. Manufactured for: UCB Pharma, Inc. Smyrna, GA 30080. by Pfizer Pharmaceuticals LLC Caguas, PR 00725. 04/2005.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) or another drug or occurrence of adverse effects without a change in serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance is altered by another drug resulting in increased or decreased serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations. Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) only rarely alters the pharmacokinetics of other drugs.
The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION). The information in the “Effect ” column of Table II assumes that the interacting drug is being added to a steady-state Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) regimen. If Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is being initiated in a patient who is already taking a drug that inhibits Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance (e.g., cimetidine, erythromycin), the dose of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) required to achieve a therapeutic serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration will be smaller. Conversely, if Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) is being initiated in a patient who is already taking a drug that enhances Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance (e.g., rifampin), the dose of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) required to achieve a therapeutic serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration will be larger. Discontinuation of a concomitant drug that increases Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance will result in accumulation of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) to potentially toxic levels, unless the Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance will result in decreased serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations, unless the Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) dose is appropriately increased.
The drugs listed in Table III have either been documented not to interact with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) or do not produce a clinically significant interaction (i.e., < 15% change in Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance).
The listing of drugs in Table II is current as of June 2004. The listing of drugs in Table III is current as of January 2, 1996. New interactions are continuously being reported for Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION), especially with new chemical entities. The healthcare professional should not assume that a drug does not interact with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) if it is not listed in Table II. Before addition of a newly available drug in a patient receiving Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION), the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) has been reported.
Table II. Clinically significant drug interactions with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION)*.
Higher doses of adenosine may be required to achieve desired effect.
Alcohol
A single large dose of alcohol (3 mL/kg of whiskey) decreases Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance for up to 24 hours.
Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) blocks adenosine receptors.
Larger diazepam doses may be required to produce desired level of sedation. Discontinuation of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) without reduction of diazepam dose may result in respiratory depression.
Disulfiram
Decreases Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance by inhibiting hydroxylation and demethylation.
50% increase
Enoxacin
Similar to cimetidine.
300% increase
Ephedrine
Synergistic CNS effects.
Increased frequency of nausea, nervousness, and insomnia.
Higher doses of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) may be required to achieve desired effect. Stopping St. John's Wort may result in Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) toxicity.
Sulfinpyrazone
Increases Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) clearance by increasing demethylation and hydroxylation. Decreases renal clearance of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION).
20% decrease
Tacrine
Similar to cimetidine, also increases renal clearance of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION).
33-100% increase depending on troleandomycin dose.
Verapamil
Similar to disulfiram.
20% increase
* Refer to PRECAUTIONS, Drug Interactions for further information regarding table.
** Average effect on steady state Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration than the value listed.
Table III. Drugs that have been documented not to interact with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) or drugs that produce no clinically significant interaction with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION).*
albuterol, systemic and inhaled
finasteride
norfloxacin
hydrocortisone
ofloxacin
amoxicillin
isoflurane
omeprazole
ampicillin, with or without sulbactam
isoniazid
prednisone, prednisolone
isradipine
ranitidine
atenolol
influenza vaccine
rifabutin
azithromycin
ketoconazole
roxithromycin
caffeine, dietary ingestion
lomefloxacin
sorbitol
cefaclor
mebendazole
(purgative doses do not inhibit Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) absorption)
co-trimoxazole (trimethoprim and sulfamethoxazole)
medroxyprogesterone
methylprednisolone
metronidazole
sucralfate
diltiazem
metoprolol
terbutaline,systemic
dirithromycin
nadolol
terfenadine
enflurane
nifedipine
tetracycline
famotidine
nizatidine
tocainide
felodipine
* Refer to PRECAUTIONS: DRUG INTERACTIONS for information regarding table.
Drug/Food Interactions
Taking Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) (Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) anhydrous capsule) ® less than one hour before a high-fat-content meal, such as 8 oz whole milk, 2 fried eggs, 2 bacon strips, 2 oz hashed brown potatoes, and 2 slices of buttered toast (about 985 calories, including approximately 71 g of fat) may result in a significant increase in peak serum level and in the extent of absorption of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) as compared to administration in the fasted state. In some cases (especially with doses of 900 mg or more taken less than one hour before a high-fat-content meal) serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) levels may exceed the 20 mcg/mL level, above which Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) toxicity is more likely to occur.
The Effect of Other Drugs on Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) Serum Concentration Measurements
Most serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) assays in clinical use are immunoassays which are specific for Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION). Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry reagent office methods to be higher than the actual serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration.
Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) side effects
Adverse reactions associated with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) are generally mild when peak serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations are < 20 mcg/ mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations exceed 20 mcg/mL, however, Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal. The transient caffeine-like adverse reactions occur in about 50%of patients when Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) therapy is initiated at doses higher than recommended initial doses (e.g., > 300 mg/day in adults and > 12 mg/kg/day in children beyond 1 year of age). During the initiation of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) therapy, caffeine-like adverse effects may transiently alter patient behavior, especially in school age children, but this response rarely persists. Initiation of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) therapy at a low dose with subsequent slow titration to a predetermined age-related maximum dose will significantly reduce the frequency of these transient adverse effects. In a small percentage of patients ( < 3%of children and < 10%of adults)the caffeine-like adverse effects persist during maintenance therapy, even at peak serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations within the therapeutic range (i.e., 10-20 mcg/mL). Dosage reduction may alleviate the caffeine-like adverse effects in these patients, however, persistent adverse effects should result in a reevaluation of the need for continued Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) therapy and the potential therapeutic benefit of alternative treatment.
Other adverse reactions that have been reported at serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations < 20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations ≥ 15 mcg/mL. There have been a few isolated reports of seizures at serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations < 20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations < 20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations < 20 mcg/mL have generally been milder than seizures associated with excessive serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).
Table IV. Manifestations of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) toxicity.*
Percentage of Patients Reported With Sign or Symptom
Acute Overdose
(Large Single Ingestion)
Chronic Overdosage
(Multiple Excessive Doses)
Sign/Symptom
Study 1
(n=157)
Study 2
(n=14)
Study 1
(n=92)
Study 2
(n=102)
Asymptomatic
NR**
0
NR**
6
Gastrointestinal
Vomiting
73
93
30
61
Abdominal Pain
NR**
21
NR**
12
Diarrhea
NR**
0
NR**
14
Hematemesis
NR**
0
NR**
2
Metabolic/Other
Hypokalemia
85
79
44
43
Hyperglycemia
98
NR**
18
NR**
Acid/base disturbance
34
21
9
5
Rhabdomyolysis
NR**
7
NR**
0
Cardiovascular
Sinus tachycardia
100
86
100
62
Other supraventricular tachycardias
2
21
12
14
Ventricular premature beats
3
21
10
19
Atrial fibrillation or flutter
1
NR**
12
NR**
Multifocal atrial tachycardia
0
NR**
2
NR**
Ventricular arrhythmias with hemodynamic instability
7
14
40
0
Hypotension/shock
NR**
21
NR**
8
Neurologic
Nervousness
NR**
64
NR**
21
Tremors
38
29
16
14
Disorientation
NR**
7
NR**
11
Seizures
5
14
14
5
Death
3
21
10
4
* These data are derived from two studies in patients with serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations > 30 mcg/mL. In the first study (Study #1 –Shanon, Ann Intern Med 1993; 119: 1161-67), data were prospectively collected from 249 consecutive cases of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) toxicity referred to a regional poison center for consultation. In the second study (Study #2 –Sessler, Am J Med 1990; 88: 567-76), data were retrospectively collected from 116 cases with serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations > 30 mcg/mL among 6000 blood samples obtained for measurement of serum Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) concentrations in three emergency departments. Differences in the incidence of manifestations of Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48%of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results.
Do not take Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) in larger or smaller amounts or for longer than recommended. Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) overdose can occur if you accidentally take too much at one time, or if your daily doses are too high. To be sure you are using the correct dose, your blood will need to be tested often.
Do not start or stop smoking without first talking to your doctor. Smoking changes the way your body uses Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION), and you may need to use a different dose.
Sometimes it is not safe to use certain drugs at the same time. Many drugs can interact with Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION). Tell your doctor about all other medicines you use. Also tell your doctor if you start or stop using any of your other medications.
Stop using Theophylline (Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION) and call your doctor at once if you have severe or continued vomiting, rapid heartbeats, confusion, tremors, or seizure.
Active ingredient matches for Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION:
DailyMed. "THEOPHYLLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Etophylline 84.7MG + THEOPHYLLINE 25.3MG INJECTION. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!